Off-campus access
Using PhilPapers from home?
Click here to configure this browser for off-campus access.
- Andrew Fenton (2009). Buddhism and Neuroethics: The Ethics of Pharmaceutical Cognitive Enhancement. Developing World Bioethics 9 (2):47-56.
Similar books and articles
This thesis argues that the neuroethical debate regarding cognitive enhancement drugs, as it stands, expounds arguments that fail as a result of the success of the Extended Cognition thesis. Instead this thesis suggets that arguments that support the ethically problemtatic nature of cognitive enhancement drugs focus on the metaphorical influence they have on the self.
Many drugs have therapeutic off-label uses for which they were not originally designed. Some drugs designed to treat neuropsychiatric and other disorders may enhance certain normal cognitive and affective functions. Because the long-term effects of cognitive and affective enhancement are not known and may be harmful, a precautionary principle limiting its use seems warranted. As an expression of autonomy, though, competent individuals should be permitted to take cognition- and mood-enhancing agents. But they need to be aware of the risks in chronic use of these agents and to take responsibility for their effects. A reasonable middle ground between these positions is to warn those who choose to enhance that doing so entails risks.
Abstract Over the past few years the use of stimulants such as methylphenidate and modafinil among the student population has attracted considerable debate in the pages of bioethics journals. Under the rubric of cognitive enhancement, bioethicists have discussed this use of stimulants—along with future technologies of enhancement—and have launched a sometimes forceful debate of such practices. In the following paper, it is argued that even if we focus solely upon current practices, the term cognitive enhancement encompasses a wide range of ethical considerations that can usefully be addressed without the need for speculation. In taking this position it is suggested that we divide cognitive enhancement into a series of empirically-constructed frameworks—medical risks and benefits, self-medication and under-prescription, prescription drug abuse and over-medication, and finally, the intention to cognitively enhance. These are not mutually exclusive frameworks, but provide a way in which to identify the scope of the issue at hand and particular ethical and medical questions that may be relevant to enhancement. By a process of elimination it is suggested that we can indeed talk of cognitive enhancement as an observable set of practices. However, in doing so we should be aware of how academic commentaries and discussion may be seen as both capturing reality and reifying cognitive enhancement as an entity. Content Type Journal Article Category Original Paper Pages 1-12 DOI 10.1007/s12152-011-9131-7 Authors Simon M. Outram, Novel Tech Ethics, Dalhousie University, 1234 Le Marchant Street, Halifax, Nova Scotia B3H 3P7, Canada Journal Neuroethics Online ISSN 1874-5504 Print ISSN 1874-5490.
The prospects of enhancing cognitive or motor functions using neuroscience in otherwise healthy individuals has attracted considerable attention and interest in neuroethics (Farah et al., Nature Reviews Neuroscience 5:421–425, 2004; Glannon Journal of Medical Ethics 32:74–78, 2006). The use of stimulants is one of the areas which has propelled the discussion on the potential for neuroscience to yield cognition-enhancing products. However, we have found in our review of the literature that the paradigms used to discuss the non-medical use of stimulant drugs prescribed for attention deficit/hyperactivity disorder (ADHD) vary considerably. In this brief communication, we identify three common paradigms—prescription drug abuse, cognitive enhancement, and lifestyle use of pharmaceuticals—and briefly highlight how divergences between paradigms create important “ethics blind spots”.
Neuroethics is a rapidly growing subfield, straddling applied ethics, moral psychology and philosophy of mind. It has clear affinities to bioethics, inasmuch as both are responses to new developments in science and technology, but its scope is far broader and more ambitious because neuroethics is as much concerned with how the sciences of the mind illuminate traditional philosophical questions as it is with questions concerning the permissibility of using technologies stemming from these sciences. In this article, I sketch the two branches of neuroethics, the applied and the philosophical, and illustrate how they interact. I also consider representative themes from each: the ethics of dampening memory and of cognitive enhancement, on the one hand, and the attack upon the reliability of deontological intuitions and upon free will, on the other.
Cognitive enhancement takes many and diverse forms. Various methods of cognitive enhancement have implications for the near future. At the same time, these technologies raise a range of ethical issues. For example, they interact with notions of authenticity, the good life, and the role of medicine in our lives. Present and anticipated methods for cognitive enhancement also create challenges for public policy and regulation.
An evaluating survey of the development of the
neuroethics of pharmaceutical cognitive enhancement
(PCE) during the last decade, focussing on
the situation in Germany, has been undertaken.
This article presents the most important conceptual
problems, current substances and central
ethical and legal issues. Very first guidelines and
recommendations for policy-makers are formulated
at the end of the text.
No categories
This article explores the respective roles that medical and technological cognitive enhancements, on the one hand, and the moral and epistemic virtues traditionally understood, on the other, can play in enabling us to lead the good life. It will be shown that neither the virtues nor cognitive enhancements (of the kind we have access to today or in the foreseeable future) on their own are likely to enable most people to lead the good life. While the moral and epistemic virtues quite plausibly are both necessary and sufficient for the good life in theory, virtue ethics is often criticised for being elitist and unachievable in practice for the vast majority. Some cognitive enhancements, on the other hand, might be necessary for the good life but are far from sufficient for such an existence. Here it will be proposed that a combination of virtue and some cognitive enhancements is preferable.
Discussion of Andrew Fenton, Buddhism and neuroethics: The ethics of pharmaceutical cognitive enhancement
|
|
There are no threads in this forum |
Nothing in this forum yet.

